Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

STEP 8

Novo Nordisk · Phase 3 · Completed · Enrollment 338

NCT04074161

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutiden/rn/rn/rn/r
Placebo (semaglutide)n/rn/rn/rn/r
Liraglutiden/rn/rn/rn/r
Placebo (liraglutide)n/rn/rn/rn/r

Not shown

  • Semaglutide: endpoint not reported
  • Placebo (semaglutide): endpoint not reported
  • Liraglutide: endpoint not reported
  • Placebo (liraglutide): endpoint not reported